NASDAQ$CRDF
Cardiff Oncology Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Cardiff Oncology reported results for Q4 2021, highlighted by clinical progress in its KRAS-mutated mCRC program, a $15 million equity investment from Pfizer, and strengthened leadership with key appointments.
Cardiff Oncology reported fourth-quarter and full-year 2021 results, highlighting continued progress in its lead KRAS-mutated metastatic colorectal cancer program, a $15 million equity investment from Pfizer, and strategic leadership appointments. The company's cash, cash equivalents, and short-term investments totaled approximately $141 million as of December 31, 2021.
- Phase 1b/2 trial in lead KRAS-mutated metastatic colorectal cancer program continues to show an objective response rate and median progression-free survival that substantially exceed those seen in historical control trials.
- Received $15 million equity investment from Pfizer through the Pfizer Breakthrough Growth Initiative.
- Adam Schayowitz, Ph.D., MBA, Vice President, Medicine Team Group Lead for Breast Cancer, Colorectal Cancer and Melanoma at Pfizer to join Cardiff Oncology Scientific Advisory Board.
- Strengthened leadership team with appointments of Tod Smeal, Ph.D., as chief scientific officer (CSO) and Charles Monahan, R.Ph., as senior vice president (SVP), regulatory affairs.
Headline financials
Revenue & EPS history
Cardiff Oncology · Revenue · Quarterly
$133K
Revenue by segment
Cardiff Oncology · $41K total across 1 segment · Q1 2026
- Royalties$41K—100.0%
Forward guidance
Cardiff Oncology is focused on advancing its mCRC clinical program, exploring synergistic combinations with onvansertib in other cancer indications, and leveraging onvansertib in other cancer indications.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2021
+2.2%
Avg return
Earnings day
+1.9%
Avg return
5 days after
+2.8%
Avg return
30 days after
43%
28 / 65 earnings
Positive
+118.2%
Q4 2010
Best reaction
-21.2%
Q4 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.8% | +3.6% | -8.3% | |
| Q4 2025 | +12.9% | +14.1% | -8.8% | |
| Q3 2025 | -3.1% | -0.4% | -6.2% | |
| Q2 2025 | -1.3% | -24.2% | -36.6% | |
| Q1 2025 | +4.0% | +2.5% | +37.4% | |
| Q4 2024 | +4.4% | +5.2% | -19.0% | |
| Q3 2024 | -19.2% | -17.6% | -39.4% | |
| Q2 2024 | +11.2% | +5.1% | -1.4% | |
| Q1 2024 | -16.8% | -21.7% | -24.8% | |
| Q4 2023 | +59.9% | +100.5% | +193.4% | |
| Q3 2023 | +5.7% | +3.8% | +20.0% | |
| Q2 2023 | -5.0% | -8.3% | -15.6% | |
| Q1 2023 | +1.1% | -4.8% | -12.4% | |
| Q4 2022 | +2.3% | +7.6% | -4.1% | |
| Q3 2022 | -4.7% | -10.7% | +5.4% | |
| Q2 2022 | +15.0% | +30.0% | +27.7% | |
| Q1 2022 | -7.7% | -11.9% | -0.7% | |
| Q4 2021 | +7.1% | +0.4% | -5.6% | |
| Q3 2021 | -5.1% | -3.6% | -14.1% | |
| Q2 2021 | +15.0% | +19.4% | +51.3% | |
| Q1 2021 | -5.5% | -13.1% | -24.5% | |
| Q4 2020 | +0.6% | +8.0% | -3.1% | |
| Q3 2020 | +10.6% | +5.8% | +26.6% | |
| Q2 2020 | -14.6% | -10.2% | -3.4% | |
| Q1 2020 | +0.8% | +6.7% | +167.5% | |
| Q4 2019 | -2.8% | +12.8% | -24.1% | |
| Q3 2019 | +1.8% | +2.4% | -20.8% | |
| Q2 2019 | -4.1% | -10.0% | +10.6% | |
| Q1 2019 | -8.1% | -11.2% | -11.2% | |
| Q4 2018 | +25.2% | +47.0% | +18.2% | |
| Q3 2018 | +6.7% | +4.0% | -6.7% | |
| Q2 2018 | -1.2% | -1.2% | +0.0% | |
| Q1 2018 | +0.0% | -3.6% | -47.3% | |
| Q4 2017 | -6.2% | -3.1% | +6.2% | |
| Q3 2017 | -1.5% | -4.4% | -26.5% | |
| Q2 2017 | -7.1% | +1.2% | -13.1% | |
| Q1 2017 | -5.0% | -1.2% | +1.3% | |
| Q4 2016 | -21.2% | -28.5% | -37.0% | |
| Q3 2016 | -5.6% | -15.5% | -29.6% | |
| Q2 2016 | -6.6% | -0.4% | -11.0% | |
| Q1 2016 | -3.7% | — | — | |
| Q4 2015 | -18.7% | — | — | |
| Q3 2015 | +11.7% | — | — | |
| Q2 2015 | -15.0% | — | — | |
| Q1 2015 | +9.6% | — | — | |
| Q4 2014 | +0.3% | — | — | |
| Q3 2014 | -1.9% | — | — | |
| Q2 2014 | +1.6% | — | — | |
| Q1 2014 | -2.3% | — | — | |
| Q4 2013 | +7.9% | — | — | |
| Q3 2013 | +12.2% | — | — | |
| Q2 2013 | -1.7% | — | — | |
| Q4 2012 | -2.4% | — | — | |
| Q1 2013 | -2.4% | — | — | |
| Q3 2012 | +2.3% | — | — | |
| Q2 2012 | -6.5% | — | — | |
| Q1 2012 | +8.8% | — | — | |
| Q4 2011 | -3.9% | — | — | |
| Q3 2011 | -17.1% | — | — | |
| Q2 2011 | +0.0% | — | — | |
| Q1 2011 | +0.0% | — | — | |
| Q4 2010 | +118.2% | — | — | |
| Q3 2010 | +0.0% | — | — | |
| Q2 2010 | +0.0% | — | — | |
| Q1 2010 | +13.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro